Scott Bizily Sells 2,678 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction on Friday, October 24th. The stock was sold at an average price of $12.00, for a total value of $32,136.00. Following the completion of the sale, the insider owned 3,594 shares of the company’s stock, valued at approximately $43,128. This represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scott Bizily also recently made the following trade(s):

• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total value of $19,256.00.

4D Molecular Therapeutics Stock Down 2.4%

Shares of FDMT opened at $11.97 on Wednesday. The company has a market cap of $559.02 million, a PE ratio of -3.39 and a beta of 2.93. The business has a fifty day moving average of $8.21 and a 200 day moving average of $5.58. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.23 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.52 million. As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on FDMT. Royal Bank Of Canada reiterated an “outperform” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Tuesday, October 21st. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.50.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BVF Inc. IL raised its position in 4D Molecular Therapeutics by 70.8% during the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock worth $14,733,000 after buying an additional 1,890,647 shares during the last quarter. Federated Hermes Inc. raised its holdings in shares of 4D Molecular Therapeutics by 33,131.8% during the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock worth $4,038,000 after purchasing an additional 1,246,419 shares during the last quarter. Acadian Asset Management LLC lifted its position in 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after purchasing an additional 367,317 shares during the period. Millennium Management LLC boosted its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after purchasing an additional 213,264 shares during the last quarter. Finally, Raymond James Financial Inc. grew its position in 4D Molecular Therapeutics by 54.7% during the 2nd quarter. Raymond James Financial Inc. now owns 455,470 shares of the company’s stock worth $1,690,000 after purchasing an additional 161,091 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.